Abstract Introduction SARS‐CoV‐2 infection is associated with hypercoagulability in patients with Coronavirus disease (COVID‐19). We used a vein‐to‐vein database to examine the impact of transfusion of plasma units from blood donors with recent SARS‐CoV‐2 infection. Study Design and Methods We linked donor SARS‐CoV‐2 serology data with plasma transfusions occurring between 6/1/2020 and 3/31/2022. Using multivariable regression, we examined changes in the international normalized ratio (INR) and subsequent transfusion requirements following plasma transfusion relative to the timing of donor SARS‐CoV‐2 nucleocapsid antibody (anti‐N Ab) positivity. Results We identified 2350 adults who received 5397 plasma units with donor SARS‐CoV‐2 serology data as part of 3721 plasma transfusion events. 8.1% (436/5397) of plasma units were from anti‐N Ab positive donors, and median time from index seropositivity to donation was 89 days (interquartile range IQR 0–210). In recipients of plasma units from recently SARS‐CoV‐2 infected donors (<120 days), the adjusted odds of a 0.25 per unit lowering of the INR were increased (aOR 1.6 1.1–2.5; p = .03) and the odds of additional plasma transfusions within 24 h were decreased (aOR 0.6 0.4–0.9; p = .04). Conclusion Recipients of plasma units from blood donors with recent SARS‐CoV‐2 infection were more likely to have post‐transfusion reductions in the INR and less likely to require additional plasma transfusions.
Roubinian et al. (Wed,) studied this question.